Prescribing Practices Program Overview

COVID-19 Information for Members regarding prescribing

Advice Regarding Take-Home Dosing (Carries) for Patients on OAT with Methadone or Suboxone

Ensuring Safe Access to M3P Prescriptions for Patients During the COVID-19 Outbreak

Appendix A: Facsimile Transmission of M3P Prescription COVID-19 Template

COVID-19 Guidance Regarding M3P Prescriptions for Palliative Care

Prescribing and Dispensing of Drugs to Treat COVID-19 - Joint Statement


The CPSM has, for several years, been working on a number of quality improvement initiatives related to the prescribing of drugs with potential for abuse. These efforts were expanded and formalized under the Prescribing Practices Program in the summer of 2018. Some components of this program are well established, while others are in the development or early implementation phase. Some of the most notable outcomes of this program are reported below.

The CPSM Prescribing Practices Program includes the following components:

·         Chief Medical Examiners` Death Review

·         High Dose Opioid Prescribing Review

·         CPSM Opioid Prescriber Profile

·         Fentanyl Prescribing Review

·         Generic Oxycontin Prescriber Education

·         Opioid Agonist Treatment (methadone and buprenorphine/naloxone) Prescriber Training, Mentoring and Auditing

·         Support around the implementation of the Opioid Prescribing Standard through online resources and individual case support/mentoring